after stopping tirzepatide Articles & Evidence Briefings Stopping Tirzepatide Led to Weight

Special shout-out to Kara

Whilst GLP-1 receptor agonists primarily work by enhancing insulin secretion rather than directly improving insulin sensitivity at the cellular level, the associated weight loss that often occurs with these medications can lead to secondary improvements in insulin resistance

In clinical trials, oral semaglutide at 14 mg demonstrated HbA1c and weight reductions broadly in line with injectable semaglutide at 0.5 mg

Some patients feel that B12 shots provide a very sustained and consistent energy level throughout the week but like to supplement and augment this effect with oral forms on particularly stressful days

Approval for Diabetes and Weight Management Over the past decade, three GLP-1/GIP receptor agonists liraglutide, semaglutide, and tirzepatide initially approved by the FDA for adults with type 2 diabetes, have also gained FDA approval for chronic weight management in people without diabetes, provided they meet specific criteria: a BMI of 30, or 27 with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes

Blasco, L